Updated Jul 16, 2026
Taub Rebecca has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $28.77M.
Rebecca Taub is a director at Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis. She has been involved in the company through multiple SEC filings.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | A — Grant or award | 454 | $0.00 | |
| 2026-03-06 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 491 | $431.94 | $212K |
| 2026-01-26 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 647 | $492.42 | $319K |
| 2026-01-20 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 2.2K | $490.77 | $1.10M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 700 | $359.71 | $252K |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 6.5K | $358.81 | $2.35M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 6.7K | $357.85 | $2.40M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 4.9K | $356.88 | $1.74M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 5.8K | $355.95 | $2.05M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 6.5K | $354.97 | $2.30M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 4.6K | $354.04 | $1.62M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 1.2K | $352.45 | $414K |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 2.9K | $351.60 | $1.01M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 3.6K | $350.87 | $1.26M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | M — Option exercise | 43.3K | $9.45 | $409K |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 220 | $351.02 | $77K |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 3.0K | $350.18 | $1.04M |
| 2025-08-11 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | M — Option exercise | 3.2K | $9.45 | $30K |
| 2025-07-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | S — Open-market sale | 1.0K | $350.00 | $350K |
| 2025-07-18 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | M — Option exercise | 1.0K | $9.45 | $9K |
Rebecca Taub is a director at Madrigal Pharmaceuticals, Inc., a biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis. She has been involved in the company through multiple SEC filings.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 25 open-market sales ($28.77M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Taub Rebecca profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.